Opdivo Qvantig, nivolumab
Named-patient access overview. Opdivo Qvantig is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Opdivo Qvantig
Opdivo Qvantig (nivolumab) is manufactured by Bristol Myers Squibb and indicated for approved across most solid tumor indications for which IV nivolumab is approved, see full prescribing information. It is a subcutaneous PD-1 inhibitor co-formulated with hyaluronidase approved by the US FDA in 2024 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Opdivo Qvantig
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Opdivo Qvantig for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Opdivo Qvantig is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Opdivo Qvantig in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Opdivo Qvantig
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.